For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
From the earliest days of when the Affordable Care Act (ACA) was being drafted to the day it was approved, a preventive services provision was a major goal to reduce cost barriers to the interventions that were proven to save downstream costs, explained Nick Bath, partner, health, law firm Manatt.
However, this year, required coverage of preventive care services under the ACA is at risk due to the lawsuit Braidwood v Becerra, which was at the heart of session that took place as part of the University of Michigan Center for Value-Based Insurance Design (V-BID)’s 2024 V-BID Summit. The theme of the V-BID Summit was “Overcoming Financial Toxicity,” and coverage of preventive care services at low or no cost can play a key role in doing so.
Bath was joined by Anand Parekh, MD, chief medical advisor, Bipartisan Policy Center, who provided the background on prevention and the importance of giving people access to preventive services, such as immunizations, cancer screenings, or substance abuse counseling, and other services that organizations like the US Preventive Services Task Force (USPSTF) have identified as being high value.
“These services save lives, they improve health, they reduce illness burden, and they really work,” he said.
However, uptake of these services in the US is poor, he added. The US does well at cardiovascular screenings, but uptake for substance use, mental health, and depression screenings are low, and immunizations are down across the board, according to Parekh.
The US has had low uptake of high-value, evidence-based clinical preventive services for a long time in both the commercial and Medicare sector, and there are a lot of reasons for that, one of which is the cost. Since the ACA was passed, research has shown that removing cost sharing from preventive services increased screening for color cancer, high blood pressure, and high cholesterol; increased vaccinations for the flu and human papillomavirus; and increased use of contraception.
“Not only that…the use of preventive services [has particularly] increased amongst those who are financially vulnerable, as well as minority populations,” Parekh said. “That’s what makes this case, Braidwood v Becerra, so important, because we know that these are really impactful services.”
The worst-case scenario, should the plaintiffs in the case prevail in removing the requirement that insurers, would be the US going “back to the Wild West,” he said, in which plans set their own rules and guidelines. However, with research showing the benefit to plan members when preventive services are available with no cost barriers, a lot of the major health plans have said they support covering these services, according to Parekh.
“Worst-case scenario, you could go back to the days where I may recommend, as a clinician, ‘it's now important to get your colorectal cancer screening,’ and the response might be, ‘well, I don't have the $500 to pay for that,’” Parekh explained. “And that's exactly what we were trying to get away from with this ACA provision.”
The Braidwood v Becerra case alleges that the USPSTF doesn’t have the specific power to deem certain preventive services require no cost in the commercial market, explained Bath. The argument is that the provision is unsound under the appointment clause, which requires certain officials performing certain tasks be appointment by the president and confirmed by the Senate or appointed by a Cabinet secretary.
In addition to ruling on the question of USPSTF’s power, the court also ruled that the Religious Freedom Restoration Act protected the nonprofit Christian-owned Braidwood Management from being required to cover pre-exposure prophylaxis drugs for HIV. The case went onto the Fifth Circuit Court of Appeals, which heard oral arguments early in March.
While the appeals court has not issued a decision, “I think a betting person would say they’re inclined to uphold the district ruling on both counts,” Bath said. “Much of the questioning during the oral argument surrounded what remedy the court should prescribe.”
Assuming the Supreme Court, which leans conservative same as the Fifth Circuit Court of Appeals, will agree, the question arises: how does one cure the appointments clause issue? The solution would have to be legislative and a bipartisan fix required. Coverage of these preventive services has enormous popularity. “They're baked into the cake now; no one expects to pay for these,” Bath said.
He added that the last 15 years have clearly shown people don’t like it when something they have is taken away, especially in health care. However, there are obstacles. These benefits have been in existence for a long time, but the fact that the cost has disappeared from peoples’ out-of-pocket liability “makes them somewhat invisible,” Bath explained.
“To put it simply, people take [covered preventive services] for granted and may not know where they came from,” he said. “In fact, they probably don’t.”
In addition, there aren’t huge cost saving associated with covering preventive services. The Congressional Budget Office does not want to assign large, downstream federal savings in the form of avoided medical care partly because there is the assumption that insurance plans will continue to cover these services even if the provision goes away.
While there does seem to be evidence that many plans will still cover these services, things change. “What happens when a screening test for cancer arises, for which the price is something unexpected? I think the plan and self-insured [employer] dynamic may look a little different because they have fiduciary duties, not because they're bad people,” Bath said.
Ultimately, he thinks that after a long appeal, which could take to the end of 2025, the appointments clause issue will land in Congress’ court. However, his concern is that this will no longer be a priority anymore and that there is no bipartisan consensus foundation on which to proceed for addressing the issue.
At the end of the session, Parekh urged attendees to make coverage of preventive care services a top priority. “At the end of the day, we all care about health, and these are services that save lives, they do help.”
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More